Table 3.

Ongoing phase III immunotherapy trials in mCRPC

Trial	National clinical trial identifier	Status*
PSA-TRICOM +/- GM-CSF	NCT01322490	Ongoing, Expected completion date June 2017
Tasquinimod	NCT01234311	Completed, Reported in 2016 [61]
Ipilimumab in chemo-naïve mCRPC	NCT01057810	Completed, Reported in 2016 [38]

* As determined by ClinicalTrials.gov accessed October 31, 2016